Quantcast FDA Approvals FDA Approvals

​FDA Approvals

 

 

Expanding Molecularly Targeted Therapy to Additional Types of Lymphoma2060The FDA has expanded the use of a CD30-targeted antibody–drug conjugate to include two additional types of lymphoma.12/13/2017 3:20:36 PM16https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1711053_LymphDrug_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding Molecularly Targeted Therapy to Additional Types of LymphomaThe FDA has expanded the use of a CD30-targeted antibody–drug conjugate to include two additional types of lymphoma.59
Targeting a Rare Blood Cancer2043The molecularly targeted therapeutic vemurafenib is the first ever treatment approved by the FDA for treating Erdheim-Chester disease.12/13/2017 2:35:00 PM177https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1711052_EChester_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting a Rare Blood CancerThe molecularly targeted therapeutic vemurafenib is the first ever treatment approved by the FDA for treating Erdheim-Chester disease.58
A New Molecularly Targeted Therapeutic for Non-Hodgkin Lymphoma28599The newly approved therapeutic is for certain patients with an aggressive type of non-Hodgkin lymphoma called mantle cell lymphoma.11/21/2017 8:11:11 PM568https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1711027A_MantleCell_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Molecularly Targeted Therapeutic for Non-Hodgkin LymphomaThe newly approved therapeutic is for certain patients with an aggressive type of non-Hodgkin lymphoma called mantle cell lymphoma.57
FDA Approves Second CAR T–cell Immunotherapy28567The second of a groundbreaking new type of immunotherapy called CAR T–cell therapy is approved for certain types of non-Hodgkin lymphoma.11/21/2017 7:14:15 PM518https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1711028A_CARTCell_150x190_1.jpg" style="BORDER&#58;0px solid;" />FDA Approves Second CAR T–cell ImmunotherapyThe second of a groundbreaking new type of immunotherapy called CAR T–cell therapy is approved for certain types of non-Hodgkin lymphoma.56
A New Molecularly Targeted Therapeutic for Breast Cancer5126The FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of the disease.10/17/2017 7:46:40 PM904https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1710006A_BreastCancer_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Molecularly Targeted Therapeutic for Breast CancerThe FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of the disease.55
Expanding the Use of an Immunotherapeutic to Liver Cancer5078The FDA decision means the immune checkpoint inhibitor nivolumab is now approved for eight types of cancer.10/13/2017 2:12:51 PM968https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1710004A_Nivolumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding the Use of an Immunotherapeutic to Liver CancerThe FDA decision means the immune checkpoint inhibitor nivolumab is now approved for eight types of cancer.54
Immunotherapy for Stomach Cancer4582The FDA has approved pembrolizumab for treating certain patients with advanced stomach (gastric) cancer.10/12/2017 1:31:04 PM1094https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1710005A_Stomach_150x190_1.jpg" style="BORDER&#58;0px solid;" />Immunotherapy for Stomach CancerThe FDA has approved pembrolizumab for treating certain patients with advanced stomach (gastric) cancer.53
Targeting Non-Hodgkin Lymphoma525A new molecularly targeted therapeutic to treat certain patients with follicular lymphoma, a common type of non-Hodgkin lymphoma, has been approved.10/10/2017 8:18:50 PM583https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709114A_Targeting_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Non-Hodgkin LymphomaA new molecularly targeted therapeutic to treat certain patients with follicular lymphoma, a common type of non-Hodgkin lymphoma, has been approved.52
Groundbreaking New Immunotherapy Approved for Acute Lymphoblastic Leukemia (ALL)20893The U.S. Food and Drug Administration has approved the first of a new type of immunotherapy called CAR T–cell therapy for ALL.9/8/2017 6:32:58 PM1879https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709009_Tcelltherapy_150x190_1.jpg" style="BORDER&#58;0px solid;" />Groundbreaking New Immunotherapy Approved for Acute Lymphoblastic Leukemia (ALL)The U.S. Food and Drug Administration has approved the first of a new type of immunotherapy called CAR T–cell therapy for ALL.47
Targeting Adult Acute Lymphoblastic Leukemia25404The FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL.9/19/2017 3:20:47 PM510https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709008_Ozogamicin_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Adult Acute Lymphoblastic LeukemiaThe FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL.51

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300